Relapse-free survival (RFS) curves (A) and RFS curves according to mastocytosis subtypes (B); overall survival (OS) of the 68 patients treated by 2-CdA (C) and OS according to mastocytosis subtypes (D). ASM, aggressive systemic mastocytosis; AHNMD, associated hematologic non–mast cell disease; CM, cutaneous mastocytosis; ISM, indolent systemic mastocytosis; SSM, smoldering systemic mastocytosis.